Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXN-188 for Migraine with Aura
NCT00920686Phase 2Completed
- Sponsor
- NeurAxon Inc.
- Start
- Jun 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NXN-188 in migraine with aura (3 arms), sponsored by NeurAxon Inc. Primary endpoint: Time to First Use of Rescue Medication at 24 hours. Started Jun 2009; status: completed.
02
Drugs
NXN-188
03
Conditions
migraine with aura
Beyond the preview
Go deeper on NCT00920686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920686.